Trial · NCT00090220
Results by group228
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 228
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence Rate of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer | qHPV in Base Study | 0.2 | Incidence per 100 person-years | ||
| Incidence Rate of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer | Placebo in Base Study | 1.7 | Incidence per 100 person-years | ||
| Number of Participants With Vaccine- or Placebo-Related Serious Adverse Events (SAEs) in the Base Study | qHPV in Base Study | 0 | Participants | ||
| Number of Participants With Vaccine- or Placebo-Related Serious Adverse Events (SAEs) in the Base Study | Placebo in Base Study | 0 | Participants | ||
| Number of Participants With Vaccine-Related SAEs After Vaccine Administration | qHPV in Base Study | 0 | Participants | ||
| Number of Participants With Vaccine-Related SAEs After Vaccine Administration | Placebo in Base Study | 1 | Participants | ||
| Number of Participants With an SAE Resulting in Death After Vaccine Administration | qHPV in Base Study: All Participants | 8 | Participants | ||
| Number of Participants With an SAE Resulting in Death After Vaccine Administration | Base Study: Placebo | 4 | Participants | ||
| Cumulative Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN) or Condyloma: Day 1 to Year 4 | qHPV in Base Study | 0.0006 | 95% Confidence Interval 0.0001 to 0.0045 | Cumulative Incidence Probability | |
| Cumulative Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN) or Condyloma: Day 1 to Year 4 | Placebo in Base Study | 0.0124 | 95% Confidence Interval 0.0079 to 0.0195 | Cumulative Incidence Probability | |
| Cumulative Incidence of HPV 6/11/16/18-related CIN or Condyloma: Year 4 to 8 | qHPV in Base Study | 0.0000 | 95% Confidence Interval 0.0000 to 0.0000 | Cumulative Incidence Probability | |
| Cumulative Incidence of HPV 6/11/16/18-related CIN or Condyloma: Year 6 to 10 | qHPV in Base Study | 0.0000 | 95% Confidence Interval 0.0000 to 0.0000 | Cumulative Incidence Probability | |
| Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Day 1 to Year 4 | qHPV in Base Study | 0.0 | 95% Confidence Interval 0.0 to 0.1 | Incidence per 100 person-years | |
| Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Day 1 to Year 4 | Placebo in Base Study | 0.4 | 95% Confidence Interval 0.2 to 0.6 | Incidence per 100 person-years | |
| Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Year 4 to 8 | qHPV in Base Study | 0.0 | 95% Confidence Interval 0.0 to 0.2 | Incidence per 100 person-years | |
| Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Year 6 to 10 | qHPV in Base Study | 0.0 | 95% Confidence Interval 0.0 to 0.2 | Incidence per 100 person-years | |
| Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 1 Month Postdose 3 in the Base Study | qHPV in Base Study: All Participants | HPV Type 6: n=1249, 605, 644 | 416.2 | 95% Confidence Interval 391.9 to 442.0 | mMU/mL |
| Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 1 Month Postdose 3 in the Base Study | qHPV in Base Study: Participants 24 to 34 Years Old | HPV Type 6: n=1249, 605, 644 | 437.4 | 95% Confidence Interval 401.2 to 476.8 | mMU/mL |
| Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 1 Month Postdose 3 in the Base Study | qHPV in Base Study: Participants 35 to 45 Years Old | HPV Type 6: n=1249, 605, 644 | 397.3 | 95% Confidence Interval 365.4 to 431.9 | mMU/mL |
| Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 1 Month Postdose 3 in the Base Study | qHPV in Base Study: All Participants | HPV Type 11: n=1249, 605, 644 | 551.2 | 95% Confidence Interval 520.5 to 583.6 | mMU/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00090220/results